Safety Evaluation of Aminophylline and Methazolamide


This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.

Full Title of Study: “The Safety Evaluation of Aminophylline and Methazolamide When Administered Orally Alone and in Combination to Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2012

Detailed Description

After successful completion of this safety trial, our goal will be to evaluate the safety of this combination in healthy individuals exposed to hypoxia and exercise. Subsequently, an efficacy study will clarify whether this drug combination improves physical and mental functions in human subjects under high altitude conditions.


  • Drug: Aminophylline
    • Aminophylline dosage form-tablet dosage-500mg
  • Drug: Methazolamide
    • Methazolamide dosage form-tablet dosage-250mg
  • Drug: Aminophylline and Methazolamide
    • Aminophylline 500mg orally and Methazolamide 250mg orally

Arms, Groups and Cohorts

  • Active Comparator: Sequence A
    • Aminophylline, Methazolamide, Aminophylline and Methazolamide
  • Active Comparator: Sequence B
    • Methazolamide, Aminophylline, Aminophylline and Mathazolamide

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Events.
    • Time Frame: 6 days.
    • Adverse event data was evaluated for incidence and severity for 6 days.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects must be healthy non-smoking adult male and female volunteers between the ages of 18 and 40 years, with a BMI of 18-30 kg/m2 and weighting at least 150 lbs. Women who are of childbearing potential, must, if sexually active, must agree to use appropriate contraceptive measures for the duration of the study and for one (1) month afterwards. – Subjects must agree not to donate blood, plasma, platelets, or any other blood components during the study and for 4 weeks after the last dose. Exclusion Criteria:

  • History or manifestation of clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematologic or other medical disorders. – Serious mental or physical illness within the past year. – History of clinically significant illness within 4 weeks prior to Day 1. – History of allergic reaction, hypersensitivity or idiosyncratic reaction to any of the products administered during the study, including allergy to any sulfa or sulfonamide derivatives. – Use of any of the following: – Any concomitant medication. Subjects who have received any prescribed or non-prescribed (over-the-counter [OTC]) systemic medication, topical medications, or herbal supplements within 14 days from Day 1. St. John's Wort (hypericin) must not have been taken for at least 30 days prior to Period 1, Day 1. – Any drugs, foods or substances known to be strong inhibitors or strong inducers of CYP enzymes (also known as cytochrome P450 enzymes); especially CYP 1A2, or Pgp within 30 days prior to Period 1, Day 1. – Currently abusing drugs or alcohol or with a history of drug or alcohol abuse within the past two years. – Positive results on screening tests for drugs of abuse, cotinine or alcohol at screening or the pre-dose assessment at check-in. – Clinically significant ECG abnormality, in the opinion of the Investigator. – Use of tobacco products or other nicotine-containing products (including smoking cessation aids, such as gums or patches) with in 14 days of screening and throughout hospitalization. – Subjects of childbearing potential who are pregnant (as based on test results) or are breast feeding. – Has taken any other investigational drug during the 30 days prior to the screening visit or is currently participating in another investigational clinical trial. – Subjects who have made any significant donation (including plasma) or have had a significant loss of blood within 30 days prior to Period 1, Day 1. Receipt of a transfusion or any blood products within 30 days prior to Period 1, Day 1.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Poudre Valley Health System
  • Collaborator
    • Defense Advanced Research Projects Agency
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gary J. Luckasen, MD, Prinicipal Investigator – Poudre Valley Health System
  • Overall Official(s)
    • Gary Luckasen, M.D., Principal Investigator, Poudre Valley Health System

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.